This article is more than 5 years old. Information may no longer be current.

Novagali Pharma receives FDA clearance for phase 3 trial of potential glaucoma treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EVRY, France — Novagali Pharma has been granted an investigational new drug application by the U.S. Food and Drug Administration, allowing the company to conduct a phase 3 clinical trial of Catioprost for glaucoma, the company announced in a press release.

Catioprost (Nova21027), the topical ocular BAK-free formulation of latanoprost, also contains Novasorb, which provides ocular surface benefits through cationic emulsion.

"We expect Catioprost to bring significant safety and comfort improvement for glaucoma patients, especially for those suffering from ocular surface diseases," Jerome Martinez, president and CEO of Novagali Pharma, said in the release.